WO2017086385A8 - Ｐａｒ１阻害をメカニズムとする異所性骨化の治療薬剤 - Google Patents

Ｐａｒ１阻害をメカニズムとする異所性骨化の治療薬剤 Download PDF

Info

Publication number
WO2017086385A8
WO2017086385A8 PCT/JP2016/084101 JP2016084101W WO2017086385A8 WO 2017086385 A8 WO2017086385 A8 WO 2017086385A8 JP 2016084101 W JP2016084101 W JP 2016084101W WO 2017086385 A8 WO2017086385 A8 WO 2017086385A8
Authority
WO
WIPO (PCT)
Prior art keywords
par1
blocking
ectopic ossification
fop
treatment drug
Prior art date
Application number
PCT/JP2016/084101
Other languages
English (en)
French (fr)
Other versions
WO2017086385A1 (ja
Inventor
択実 江良
貴之 木ト
Original Assignee
国立大学法人 熊本大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人 熊本大学 filed Critical 国立大学法人 熊本大学
Priority to EP16866386.2A priority Critical patent/EP3378490B1/en
Priority to US15/776,152 priority patent/US20200253942A1/en
Priority to JP2017551922A priority patent/JP6873410B2/ja
Publication of WO2017086385A1 publication Critical patent/WO2017086385A1/ja
Publication of WO2017086385A8 publication Critical patent/WO2017086385A8/ja
Priority to US17/106,565 priority patent/US20210161872A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

【課題】FOP患者における病態メカニズムをより明らかにするとともに，得られた知見を活かした新たな治療薬や治療方法，診断方法等の開発。 【解決手段】発明者らは，FOPにおいて，外傷等による炎症をきっかけとして生じる異所性骨化が，PAR1を介して起こっているという新たな知見を見出した。発明者らはこの知見から，PAR1を阻害することにより，FOPの異所性骨化を抑制することを特徴とする薬剤等にかかる発明を完成させたものである。
PCT/JP2016/084101 2015-11-20 2016-11-17 Ｐａｒ１阻害をメカニズムとする異所性骨化の治療薬剤 WO2017086385A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP16866386.2A EP3378490B1 (en) 2015-11-20 2016-11-17 Ectopic ossification treatment drug having mechanism for blocking par1
US15/776,152 US20200253942A1 (en) 2015-11-20 2016-11-17 Therapeutic drug for ectopic ossification having mechanism to inhibit par1
JP2017551922A JP6873410B2 (ja) 2015-11-20 2016-11-17 Ｐａｒ１阻害をメカニズムとする異所性骨化の治療薬剤
US17/106,565 US20210161872A1 (en) 2015-11-20 2020-11-30 Therapeutic drug for ectopic ossification having mechanism to inhibit par1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-228232 2015-11-20
JP2015228232 2015-11-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/776,152 A-371-Of-International US20200253942A1 (en) 2015-11-20 2016-11-17 Therapeutic drug for ectopic ossification having mechanism to inhibit par1
US17/106,565 Division US20210161872A1 (en) 2015-11-20 2020-11-30 Therapeutic drug for ectopic ossification having mechanism to inhibit par1

Publications (2)

Publication Number Publication Date
WO2017086385A1 WO2017086385A1 (ja) 2017-05-26
WO2017086385A8 true WO2017086385A8 (ja) 2018-01-18

Family

ID=58718886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/084101 WO2017086385A1 (ja) 2015-11-20 2016-11-17 Ｐａｒ１阻害をメカニズムとする異所性骨化の治療薬剤

Country Status (4)

Country Link
US (2) US20200253942A1 (ja)
EP (1) EP3378490B1 (ja)
JP (1) JP6873410B2 (ja)
WO (1) WO2017086385A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020135812A1 (en) 2018-12-29 2020-07-02 Shanghai United Imaging Intelligence Co., Ltd. Systems and methods for ossification center detection and bone age assessment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140378502A1 (en) * 2011-05-12 2014-12-25 UNIVERSITé LAVAL Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections
WO2015054718A1 (en) * 2013-10-18 2015-04-23 The University Of Sydney Bone formation
JP6601687B2 (ja) * 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤

Also Published As

Publication number Publication date
US20210161872A1 (en) 2021-06-03
EP3378490A1 (en) 2018-09-26
EP3378490B1 (en) 2020-07-15
WO2017086385A1 (ja) 2017-05-26
JPWO2017086385A1 (ja) 2018-09-06
US20200253942A1 (en) 2020-08-13
EP3378490A4 (en) 2019-07-31
JP6873410B2 (ja) 2021-05-19

Similar Documents

Publication Publication Date Title
PH12017500493A1 (en) Combination therapy
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
IL272601A (en) Pharmaceutical preparations for the treatment of ophthalmic conditions
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
PL3268029T3 (pl) Leczenie pacjentów z cukrzycą typu 2
ZA202002993B (en) Compounds for the treatment of neuromuscular disorders
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
WO2015001541A3 (en) Pharmaceutical film composition
WO2017086385A8 (ja) Ｐａｒ１阻害をメカニズムとする異所性骨化の治療薬剤
SG11201707467PA (en) Treatment of type 2 diabetes mellitus patients
HK1259373A1 (zh) 用於治療糖尿病的藥物製劑
WO2016020408A3 (en) Compounds for preventing ototoxicity
IL256919A (en) Pharmaceutical compositions useful for the treatment of tissue damage
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
IL251392B (en) Transformed aromatic compounds and their pharmaceutical preparations for the prevention and treatment of diabetes
PL3217975T3 (pl) Zastosowanie skutecznych pod względem immunomodulacji kompozycji do immunoterapeutycznego leczenia pacjentów z białaczką szpikową
MA40065A (fr) N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
EP3189846A4 (en) Pharmaceutical composition for prevention or treatment neuro-inflammation or neurodegenerative diseases comprising Portulaca grandiflora Hook. extracts or fractions thereof
MX2015001677A (es) Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion.
IL287529B (en) A pharmaceutical combination that includes trazodone for the treatment of neuropathic pain
PT3724173T (pt) Compostos para o tratamento de distúrbios neuromusculares
AU2016905281A0 (en) Pharmaceutical composition for treatment of an eye disease or condition
AU2016904360A0 (en) Pharmaceutical composition for treatment of an eye disease or condition

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16866386

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017551922

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016866386

Country of ref document: EP